KR20080040631A - 에프린 신호전달과 관련된 질환을 쿠프레독신으로 치료하기위한 조성물과 방법 - Google Patents

에프린 신호전달과 관련된 질환을 쿠프레독신으로 치료하기위한 조성물과 방법 Download PDF

Info

Publication number
KR20080040631A
KR20080040631A KR1020077028984A KR20077028984A KR20080040631A KR 20080040631 A KR20080040631 A KR 20080040631A KR 1020077028984 A KR1020077028984 A KR 1020077028984A KR 20077028984 A KR20077028984 A KR 20077028984A KR 20080040631 A KR20080040631 A KR 20080040631A
Authority
KR
South Korea
Prior art keywords
cupredoxin
cancer
ala
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077028984A
Other languages
English (en)
Korean (ko)
Inventor
아난다 차카라바티
타파스 다스 구프타
토루 야마다
아니타 차우다하리
아르세니오 피알로
용후아 쥬
Original Assignee
더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 filed Critical 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이
Publication of KR20080040631A publication Critical patent/KR20080040631A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020077028984A 2005-05-20 2006-05-19 에프린 신호전달과 관련된 질환을 쿠프레독신으로 치료하기위한 조성물과 방법 Ceased KR20080040631A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US60/682,812 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US11/244,105 2005-10-06
US76474906P 2006-02-03 2006-02-03
US60/764,749 2006-02-03

Publications (1)

Publication Number Publication Date
KR20080040631A true KR20080040631A (ko) 2008-05-08

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028984A Ceased KR20080040631A (ko) 2005-05-20 2006-05-19 에프린 신호전달과 관련된 질환을 쿠프레독신으로 치료하기위한 조성물과 방법

Country Status (10)

Country Link
EP (1) EP1888106A4 (cg-RX-API-DMAC10.html)
JP (1) JP2008539795A (cg-RX-API-DMAC10.html)
KR (1) KR20080040631A (cg-RX-API-DMAC10.html)
AU (1) AU2006277009A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612424A2 (cg-RX-API-DMAC10.html)
CA (1) CA2608512A1 (cg-RX-API-DMAC10.html)
IL (1) IL187138A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007014598A (cg-RX-API-DMAC10.html)
NO (1) NO20076391L (cg-RX-API-DMAC10.html)
WO (1) WO2007018671A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
EP2061498A4 (en) * 2006-09-14 2009-11-04 Univ Illinois COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES
WO2008086523A2 (en) * 2007-01-11 2008-07-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
WO2023205752A2 (en) * 2022-04-22 2023-10-26 University Of Miami Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases
TW202547871A (zh) * 2024-03-27 2025-12-16 美商麥第爾醫療公司 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076380A2 (en) * 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도

Also Published As

Publication number Publication date
BRPI0612424A2 (pt) 2009-01-27
IL187138A0 (en) 2008-02-09
JP2008539795A (ja) 2008-11-20
AU2006277009A1 (en) 2007-02-15
NO20076391L (no) 2008-02-15
MX2007014598A (es) 2008-02-07
EP1888106A2 (en) 2008-02-20
WO2007018671A3 (en) 2007-11-22
CA2608512A1 (en) 2007-02-15
EP1888106A4 (en) 2009-01-14
WO2007018671A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US10889621B2 (en) Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
US7511117B2 (en) Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US8017749B2 (en) Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
US10058585B2 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US20140179617A1 (en) Cytotoxic Factors For Modulating Cell Death
WO2008033820A2 (en) Modifications of cupredoxin derived peptides and methods of use thereof
AU2006277009A1 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
KR20080024124A (ko) 쿠프레독신과 시토크롬 ｃ로 ｈｉｖ 감염을 치료하기 위한조성물과 방법
WO2008086523A2 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
CN101198351A (zh) 用铜氧还蛋白治疗ephrin信号传导相关性病变的组合物和方法
KR20080019615A (ko) 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
US10266868B2 (en) Compositions for treating HIV infection with cupredoxin and cytochrome C
KR20080034905A (ko) 쿠프레독신으로 혈관신생을 제어하는 조성물과 방법
CN101223283A (zh) 用铜氧还蛋白和细胞色素治疗疟疾的组合物和方法
MXPA06001820A (en) Use of polypeptides of the cupredoxin family in cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110517

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121206

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130605

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20121206

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I